Eyenovia Investor Relations Material

Eyenovia Inc operates as a commercial-stage ophthalmic technology company. Its primary focus is on the commercialization of Mydcombi, a proprietary ophthalmic spray for mydriasis (pupil dilation) composed of tropicamide and phenylephrine, and the development of the Optejet device. The Optejet is designed for use in drug-device therapeutic product candidates for conditions such as presbyopia and pediatric progressive myopia, as well as for out-licensing for additional indications. Eyenovia's approach aims to change ocular drug delivery by achieving clinical microdosing of next-generation formulations of established pharmaceutical agents through its high-precision targeted ocular delivery system, potentially offering an alternative to conventional eyedropper delivery methods. The company is headquartered in NYC and its shares are listed on the Nasdaq.